PRESS RELEASES

Date Title and Summary View
Jul 2, 2018
Summary ToggleZafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares

BOSTON , July 02, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced the closing of its previously

Summary ToggleZafgen Announces Closing of Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Common Shares
Jun 28, 2018
Summary ToggleZafgen Announces Pricing of Offering of Common Stock

BOSTON , June 28, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced the pricing of its previously

Summary ToggleZafgen Announces Pricing of Offering of Common Stock
Jun 27, 2018
Summary ToggleZafgen Announces Proposed Offering of Common Stock

BOSTON , June 27, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, today announced that it has commenced an

Summary ToggleZafgen Announces Proposed Offering of Common Stock
Jun 25, 2018
Summary ToggleZafgen Set to Join Russell 3000® Index

BOSTON , June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel therapies for patients affected by complex metabolic diseases, is set to join the Russell 3000 ® Index at the

Summary ToggleZafgen Set to Join Russell 3000® Index
Jun 25, 2018
Summary ToggleREMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call

BOSTON , June 25, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, will host an investor conference call today, Monday, June 25 ,

Summary ToggleREMINDER: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call
Jun 23, 2018
Summary ToggleZafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes

Trial met all primary objectives, demonstrated efficacy and safety and established minimally effective dose of 0.9 mg for ZGN-1061 Patient dosing recently initiated for the 1.8 mg dose cohort Zafgen presenting the Phase 2 clinical data and data from two supportive nonclinical studies at the

Summary ToggleZafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes
Jun 7, 2018
Summary ToggleZafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors

Zafgen, Inc. also announces the retirements of Dr. Bruce Booth and Ms. Frances Heller from its Board of Directors BOSTON , June 07, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary MetAP2 biology platform to develop novel

Summary ToggleZafgen, Inc. Appoints Industry Veteran and Healthcare Policy Expert Dr. Wendy Everett to its Board of Directors
May 30, 2018
Summary ToggleZafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer

BOSTON , May 30, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. , (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today the appointment of Brian McVeigh as Chief Business

Summary ToggleZafgen, Inc. Expands Executive Leadership Team with Appointment of Brian McVeigh as Chief Business Officer
May 8, 2018
Summary ToggleZafgen Reports First Quarter 2018 Operating and Financial Results

Multiple ZGN-1061 abstracts accepted for presentation at upcoming American Diabetes Association (ADA) Scientific Sessions ZGN-1061 Phase 1 SAD / MAD data published in Diabetes, Obesity and Metabolism BOSTON , May 08, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage

Summary ToggleZafgen Reports First Quarter 2018 Operating and Financial Results
May 2, 2018
Summary ToggleZafgen to Present at Deutsche Bank 43rd Annual Health Care Conference

BOSTON , May 02, 2018 (GLOBE NEWSWIRE) -- Zafgen , Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that Jeffrey Hatfield,

Summary ToggleZafgen to Present at Deutsche Bank 43rd Annual Health Care Conference